DekaBank Deutsche Girozentrale’s Sagimet Biosciences SGMT Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,000	Closed	-$125K	–	1320
2025 Q4	$125K	Hold	20,000	–	–	﹤0.01%	1226
2025 Q3	$136K	Hold	20,000	–	–	﹤0.01%	1187
2025 Q2	$161K	Hold	20,000	–	–	﹤0.01%	1166
2025 Q1	$73K	Hold	20,000	–	–	﹤0.01%	1258
2024 Q4	$97K	Hold	20,000	–	–	﹤0.01%	1260
2024 Q3	$56K	Hold	20,000	–	–	﹤0.01%	1347
2024 Q2	$81K	Hold	20,000	–	–	﹤0.01%	1321
2024 Q1	$113K	Buy	+20,000	New	+$144K	﹤0.01%	1246

Other funds holding SGMT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DekaBank Deutsche Girozentrale's SGMT Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Sagimet Biosciences (SGMT) in Q1 2026, closing a stake of 20,000 shares — an estimated $125K sold.

DekaBank Deutsche Girozentrale first reported a position in SGMT in Q1 2024 and held it in 8 quarters. The position peaked at $161K in Q2 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Sagimet Biosciences position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 20,000 Sagimet Biosciences shares in Q1 2026, an estimated $125K.
DekaBank Deutsche Girozentrale first reported a position in Sagimet Biosciences in Q1 2024 and held it in 8 quarters.
DekaBank Deutsche Girozentrale's Sagimet Biosciences position peaked at $161K in Q2 2025.
88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.